SEC Form 4 · accession 0001062993-18-003711
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark N Wegman
Director
Period of report
Sep 10, 2018
Accepted (ET)
Sep 11, 2018 · 9:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par valueF1 | Sep 10, 2018 | S | 5,500 | $57.3102 | D | 66,272 | D | |
| Common Stock, $0.001 par valueF2 | Sep 11, 2018 | S | 1,000 | $58.655 | D | 65,272 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $57.3102 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $56.22 to $58.902. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2The selling price of $58.655 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $58.64 to $58.67. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.